In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

The staff at the Center for a New American Security dove into researching some of the most pressing and hard-hitting national ...

"I only heard about it this morning," Park Hae-soo says. "They briefed me right before this interview. It still hasn't quite ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Explore a review of Anaconda, an absurd spoof, and The Great Flood, a disaster drama that drowns in confusing conceit. Read ...

Left Right & Center is for listeners who feel like people on the other side of the political divide are on Mars. David Greene pieces together the big picture by inviting people from the left and the ...

Nike’s iconic swoosh is limping into 2026. Their Q4 CY2025 revenue came in at $12.43 billion, topping forecasts even though ...

US stock futures jump today as Dow futures, S&P 500 futures, and Nasdaq futures turn green early Tuesday. Investors position ...